Terms: = Uterine cancer AND PPP2R1A, PR65A, 5518, ENSG00000105568, MGC786, P30153 AND Treatment
8 results:
1. ECPPF (E2F1, CCNA2, POLE, ppp2r1a, FBXW7) stratification: Profiling high-risk subtypes of histomorphologically low-risk and treatment-insensitive endometrioid endometrial cancer.
Gonzalez-Bosquet J; Weroha SJ; Bakkum-Gamez JN; Weaver AL; McGree ME; Dowdy SC; Famuyide AO; Kipp BR; Halling KC; Yadav S; Couch FJ; Podratz KC
PLoS One; 2022; 17(12):e0278408. PubMed ID: 36454788
[TBL] [Abstract] [Full Text] [Related]
2. Targeting Ribonucleotide Reductase Induces Synthetic Lethality in PP2A-Deficient uterine Serous Carcinoma.
O'Connor CM; Taylor SE; Miller KM; Hurst L; Haanen TJ; Suhan TK; Zawacki KP; Noto FK; Trako J; Mohan A; Sangodkar J; Zamarin D; DiFeo A; Narla G
Cancer Res; 2022 Feb; 82(4):721-733. PubMed ID: 34921012
[TBL] [Abstract] [Full Text] [Related]
3. uterine serous carcinoma: key advances and novel treatment approaches.
Ferriss JS; Erickson BK; Shih IM; Fader AN
Int J Gynecol Cancer; 2021 Aug; 31(8):1165-1174. PubMed ID: 34210768
[TBL] [Abstract] [Full Text] [Related]
4. uterine serous carcinoma.
Bogani G; Ray-Coquard I; Concin N; Ngoi NYL; Morice P; Enomoto T; Takehara K; Denys H; Nout RA; Lorusso D; Vaughan MM; Bini M; Takano M; Provencher D; Indini A; Sagae S; Wimberger P; Póka R; Segev Y; Kim SI; Candido Dos Reis FJ; Lopez S; Mariani A; Leitao MM; Raspagliesi F; Panici PB; Di Donato V; Muzii L; Colombo N; Scambia G; Pignata S; Monk BJ
Gynecol Oncol; 2021 Jul; 162(1):226-234. PubMed ID: 33934848
[TBL] [Abstract] [Full Text] [Related]
5. Molecular variations in uterine carcinosarcomas identify therapeutic opportunities.
Crane E; Naumann W; Tait D; Higgins R; Herzog T; Brown J
Int J Gynecol Cancer; 2020 Apr; 30(4):480-484. PubMed ID: 32114514
[TBL] [Abstract] [Full Text] [Related]
6. Targeted Therapies in Type II Endometrial cancers: Too Little, but Not Too Late.
Remmerie M; Janssens V
Int J Mol Sci; 2018 Aug; 19(8):. PubMed ID: 30104481
[TBL] [Abstract] [Full Text] [Related]
7. Refining prognosis and identifying targetable pathways for high-risk endometrial cancer; a TransPORTEC initiative.
Stelloo E; Bosse T; Nout RA; MacKay HJ; Church DN; Nijman HW; Leary A; Edmondson RJ; Powell ME; Crosbie EJ; Kitchener HC; Mileshkin L; Pollock PM; Smit VT; Creutzberg CL
Mod Pathol; 2015 Jun; 28(6):836-44. PubMed ID: 25720322
[TBL] [Abstract] [Full Text] [Related]
8. Landscape of somatic single-nucleotide and copy-number mutations in uterine serous carcinoma.
Zhao S; Choi M; Overton JD; Bellone S; Roque DM; Cocco E; Guzzo F; English DP; Varughese J; Gasparrini S; Bortolomai I; Buza N; Hui P; Abu-Khalaf M; Ravaggi A; Bignotti E; Bandiera E; Romani C; Todeschini P; Tassi R; Zanotti L; Carrara L; Pecorelli S; Silasi DA; Ratner E; Azodi M; Schwartz PE; Rutherford TJ; Stiegler AL; Mane S; Boggon TJ; Schlessinger J; Lifton RP; Santin AD
Proc Natl Acad Sci U S A; 2013 Feb; 110(8):2916-21. PubMed ID: 23359684
[TBL] [Abstract] [Full Text] [Related]
